UNSPSC 51292003: Ansoxetine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3LY71185IQ. European Medicines Agency schedules Ansoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05524MIG. Ansoxetine generally arises in the molecular formula C26H25NO3.

UNSPSC 51292003 Ansoxetine is a Commodity code that in practice sees state and local procurement activity focused on pharmaceutical supply and distribution rather than ansoxetine specifically. Recent solicitations show state and local buyers acquiring naloxone and safe drug deactivation systems, generic pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances administering on behalf of participating state and local government facilities. The work involves procuring pharmaceutical inventory, negotiating pricing and supply terms with manufacturers and wholesalers, managing distribution logistics, and ensuring compliance with FDA requirements, Good Manufacturing Practices certification, and Drug Supply Chain Security Act standards.

Procurement activity spans Florida and Texas with participation from Minnesota and Oregon through cooperative purchasing vehicles. Representative recent solicitations include Seminole County's IFB60459723LAS, an invitation for bid posted June 30, 2026 with response due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities with awards effective July 1, 2026. The MMCAP solicitation emphasizes price competitiveness (75 percent evaluation weight), compliance with manufacturing and supply chain security standards, and wholesaler relationship requirements.